FDA’s plan to ban hair relaxer chemical called too little, too late

In April, a dozen years after a federal agency classified formaldehyde a human carcinogen, the Food and Drug Administration is tentatively scheduled to unveil a proposal to consider banning the chemical in hair-straightening products.

Tessera gets up to $50M from the Gates Foundation; Tvardi’s reverse merger

Plus, news about Sensorion, Soleno Therapeutics, Corvus and Hansa Biopharma: Tessera Therapeutics bags up to $50M for sickle cell disease R&D: The investment is part

December 19, 2024

Pharmalittle: We’re reading about a CRISPR approval, selling meds directly to patients, and more

Rise and shine, everyone. The middle of the week is upon us. Have heart, though. You made it this far, so why not hang on

January 17, 2024

Officials agree: Use settlement funds to curb youth addiction. But the ‘how’ gets hairy.

When three teenagers died of fentanyl overdoses last year in Larimer County, Colorado, it shocked the community and “flipped families upside down,” said Tom Gonzales,

September 25, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.